With Fresh Funding, Senzo Looks Ahead to a New Era of Point-Of-Care Diagnostics and Growth in Philadelphia

Published on : Published by : Sarah Ellinwood

Senzo Health is working to change COVID-19 testing with its Amplified Lateral Flow (ALF) COVID-19 antigen test, which combines the sensitivity and specificity of molecular assays with the convenience of a point-of-care diagnostic, with results in under 10 minutes.

Senzo Secures a $2mm Pre-Series A Financing Led by Bioadvance to Progress Its Breakthrough Lateral Flow Diagnostic Testing Platform for Covid-19, Flu A/B, Tuberculosis, HIV

Published on : Published by : BioBuzz Media

Senzo, a life sciences company developing high accuracy, low-cost point-of-care diagnostic technologies, today announced a $2 million equity funding round led by BioAdvance, a leading life science venture capital firm. Wellness Coaches, a national provider of health and wellness solutions, including point-of-care diagnostics testing to public and private organizations, also participated in the round.